Formycon
CompanyGermanyFounded 2010
Formycon develops one asset. Mostly antibody; based in Germany, founded in 2010.
- 1
- Asset
- Furthest stage
- Not known
- 0
- Trials
- 2
- Signals
Pipeline
1Blocks PD-1 to restore antitumor T-cell activity; a proposed Keytruda biosimilar.
Stage not known, Antibody
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Signals2